focus -WSS

focus

author：comprehensive 2025-09-28 20:23:27 - browse：5

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： ACIP vaccine advisory panel sees its vacancies filled

explore

focus

WSS

STAT Boddities: What happens to the brain when we get scared?

New CMS data security rules will hurt Medicare, Medicaid research

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Bernie Sanders gets little from pharma CEOs on drug prices

Hospitals are piloting generative AI tools as regulators play catch

entertainment

focus

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Congress may force more Covid

Moonlake's readout produced a cash windfall. Risks remain

Congress might make insulin pumps more accessible to the blind

How to save PrEP access — and even expand it

New study raises questions about niacin and heart health

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

ACIP vaccine advisory panel sees its vacancies filled

Affirmative action in medical school literally saved lives

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

focus

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Reporting on presidential health from Reagan to Trump and Biden

As AI regulations shape up, health tech startups beg for clarity

Resistance to opioid

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

focus

explore

focus

focus